iTeos to Participate in Upcoming Investor Conferences

WATERTOWN, Mass. and GOSSELIES, Belgium, March 01, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming investor conferences in March:

Cowen 44^th Annual Healthcare Conference
Format: Presentation and one-on-one investor meetings
Date: Wednesday, March 6, 2024
Time: 1:30 PM ET
Location: Boston, M.A.

Leerink Partners Global Biopharma Conference
Format: One-on-one investor meetings
Date: Monday, March 11, 2024
Location: Miami, F.L.

A live webcast of the conference presentation will be available on the Investors section of the company’s website at www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation.

About iTeos Therapeutics, Inc.

iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. The Company’s innovative pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes, including the TIGIT:CD226 axis and the adenosine pathway. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.

Internet Posting of Information

iTeos Therapeutics routinely posts information that may be important to investors in the 'Investors' section of its website at www.iteostherapeutics.com. The company encourages investors and potential investors to consult our website regularly for important information about iTeos Therapeutics.

For further information, please contact:

Investor Contact:

Carl Mauch
iTeos Therapeutics, Inc.
[email protected]

Media Contact:

[email protected]

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Rocket Lab Satellite Platforms Built for MDA Space Successfully Reach Orbit, Supporting Globalstar Direct-to-Device Communications Services
• Altcoin Season Index Watch: Chainlink and Monero Run While the Large Caps Cool
• Best BNB Chain Projects: MemeToro’s Prediction Market and AI Tools Set It Apart From Four.meme